Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Progressive Digital Media Group PLC       GB00B1GCQP32

SummaryNewsCalendarCompanyFinancialsRevisions 
News SummaryMost relevantAll newsSector newsTweets

GlobalData : Type 2 diabetes market to more than double, to $64 billion by 2026

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/11/2017 | 12:27pm CEST

The type 2 diabetes space across the seven major markets of the US, France, Germany, Italy, Spain, the UK, and Japan, is set to more than double in value from $26.8 billion in 2016 to around $64 billion by 2026. While the global T2D market is crowded with inexpensive generics and marked by a late-stage pipeline filled with me-too drugs, the market is expected to grow at a strong compound annual growth rate of 8.4%, according to research and consulting firm GlobalData.

The company's latest report reveals that the dramatic increase in the prevalence, progressive nature and diagnosis of type 2 diabetes is the main driver of this rapid growth rate. The rise in disease-related comorbidities has also fuelled a more aggressive approach to treatment, including the use of multiple-drug therapies.

Current and future leaders in the type 2 diabetes space during the forecast period include Novo Nordisk, Astra Zeneca, Merck, Eli Lilly/BI, Takeda, Johnson & Johnson, Sanofi, and Intarcia Therapeutics. All of these companies have either late-stage pipeline products or very recently marketed products that have the potential to significantly strengthen their company's portfolios.

Jesus Cuaron, Ph.D., PPM, Managing Healthcare Analyst at GlobalData, explains: 'All currently available treatments for type 2 diabetes are initially effective and reduce complication rates, but they lack the ability to maintain glycemic control in the long term because of the progressive nature of pancreatic β-cell dysfunction. This represents one of the highest unmet needs in the type 2 diabetes space and demonstrates that the market has a significant growth opportunity for new patent-protected products that successfully address underlying disease pathology, cardiovascular concerns, or compliance issues.'

Overall, the ever-increasing prevalence of diabetes, along with the increased usage of anti-diabetic drugs with non-glycemic benefits, will lead to significant growth of the type 2 diabetes market.

- Information based on GlobalData's report: PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2026.

GlobalData plc published this content on 11 August 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 11 August 2017 10:26:08 UTC.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PROGRESSIVE DIGITAL MEDIA
08/16 GLOBALDATA : Brexit woes for UK mortgage market as lending slows, says GlobalDat..
08/16 GLOBALDATA : HNW female entrepreneurs represent a growing opportunity for wealth..
08/15 GLOBALDATA : Athleisure is here to stay as ASOS targets lucrative £2.5bn UK spor..
08/11 INTERNET OF THINGS (IOT) : Technology, Outlook & Significance 2017
08/11 GLOBALDATA : Type 2 diabetes market to more than double, to $64 billion by 2026
08/10 GLOBALDATA : Retail finance to be fast tracked by S40m ZipMoney Investment
08/02 GLOBALDATA : Artificial Intelligence (AI) is more important to IoT than Big Data..
08/01 GLOBALDATA : Global HER2-positive breast cancer market to face challenges from b..
08/01 GLOBALDATA : UK consumers to face 3% year-on-year food price rises until 2022
07/27 WEBINAR : Key Ingredient Trends in FMCG – What Consumers are Saying in 201..
More news
Financials ( GBP)
Sales 2017 118 M
EBIT 2017 -
Net income 2017 -
Debt 2017 20,5 M
Yield 2017 1,37%
P/E ratio 2017 -
P/E ratio 2018 -
Capi. / Sales 2017 5,04x
Capi. / Sales 2018 -
Capitalization 575 M
Income Statement Evolution
Managers
NameTitle
Michael Thomas Danson Chief Executive Officer
Bernard Anthony Cragg Chairman
Simon John Pyper Chief Financial Officer
Peter Martin Harkness Independent Non-Executive Director
Murray Legg Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
PROGRESSIVE DIGITAL MEDIA GROUP PLC740
RELX15.25%43 952
RELX N.V.10.26%43 945
S&P GLOBAL INC39.58%38 576
THOMSON REUTERS CORP-2.09%32 859
EQUIFAX INC.18.95%16 839